GENFIT's NTZ Gains FDA Orphan Drug Status for ACLF Treatment

Event summary

  • FDA grants Orphan Drug Designation to GENFIT's NTZ (nitazoxanide) for treating Acute-on-Chronic Liver Failure (ACLF).
  • G1090N, the reformulated version of NTZ, is GENFIT's lead program for ACLF, a severe condition with no approved therapies.
  • Phase 1 data shows favorable safety and tolerability in healthy volunteers, with strong anti-inflammatory activity in ex vivo models.
  • Orphan Drug Designation provides regulatory incentives, including guidance, fee reductions, and potential seven-year U.S. market exclusivity.
  • Phase 2 clinical development for G1090N is targeted for the second half of 2026.

The big picture

GENFIT's FDA Orphan Drug Designation for NTZ underscores the growing focus on rare and life-threatening liver diseases. The designation not only provides regulatory advantages but also highlights the company's strategic shift towards addressing unmet medical needs in ACLF. With Ipsen as a significant shareholder, GENFIT's ability to execute on its pipeline could influence its valuation and market standing in the biopharmaceutical sector.

What we're watching

Clinical Development
The pace at which GENFIT advances G1090N into Phase 2 trials will determine its potential to address ACLF, a condition with high short-term mortality.
Regulatory Incentives
How GENFIT leverages the FDA's Orphan Drug Designation benefits, including market exclusivity, could impact its long-term competitive positioning.
Market Strategy
Whether GENFIT can sustain momentum in its pipeline following the accelerated approval of Iqirvo® for Primary Biliary Cholangitis (PBC) in 2024.